AliveCor is the market leader for mobile EEG devices with up to 6 leads
AliveCor, Inc. is pioneering the development of FDA-approved machine learning techniques and is recognized worldwide for transforming the treatment of heart disease. The FDA-approved and CE-marked KardiaMobile is the clinically most validated mobile ECG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile and KardiaMobile 6L in combination with the Kardia app provide an immediate analysis to detect atrial fibrillation, bradycardia, tachycardia and normal rhythm in an ECG. Kardia is the first AI-enabled platform that helps physicians assist patients in the early detection of atrial fibrillation, the most common cardiac arrhythmia that leads to a five-fold higher risk of stroke. The new KardiaPro platform is the only remote patient monitoring platform that works with existing devices used by patients. AliveCor was ranked number one artificial intelligence company by Fast Company on its list of the top 50 most innovative companies, ranking 20th in a rating of thousands of companies worldwide. AliveCor has pending patent applications and patents for ideas presented in this news release, including granted US Patent Nos. 9,839,363; 9,572,499; 9,986,925; 9,833,158; 9,351,654; 9,220,430 and 9,579,062. AliveCor is a privately held company based in Mountain View, California. "Consumer" or "Personal" ECGs are ECG devices intended for direct sale to the consumer.